|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 9,814,838: Scope, Claims, and Patent Landscape
Executive Summary
US Patent 9,814,838, granted on November 14, 2017, to Regeneron Pharmaceuticals, Inc., covers a novel antibody composition targeting a specific therapeutic entity. This patent features claims that delineate both the composition's structural aspects and its therapeutic applications, positioning it firmly within the biotech pharmaceuticals landscape. Its scope emphasizes specific variable regions of the antibody, methods of production, and potential indications, especially serving as a platform for subsequent innovations in immunotherapy. An evaluation of the claims reveals a strategic focus on binding affinity and specificity, with implications for patentability, enforceability, and competitive freedom.
The patent landscape surrounding US 9,814,838 reflects a robust cluster of prior and related patents, especially within the realms of monoclonal antibody development, antigen targeting, and therapeutic use. Key players include major biotech firms such as Regeneron, Amgen, and Genentech, alongside numerous patent filings on similar targets and antibody engineering approaches. Understanding these facets informs licensing opportunities, patent validity assessments, and freedom-to-operate analyses.
What Is the Scope of US Patent 9,814,838?
Core Elements of the Scope
-
Title & Abstract:
The patent is titled "Antibodies and Related Methods", with an abstract emphasizing engineered monoclonal antibodies that bind with high specificity to a target antigen, with potential therapeutic applications.
-
Main Focus:
specificity to a particular antigen or epitope within a disease pathway, especially cancer or autoimmune disorders.
-
Claims’ Breadth & Focus:
The claims span structural antibody features, functional binding parameters, methods of production, and therapeutic uses, designed to capture both the composition and application scope.
Claim Categories and Their Coverage
| Claim Category |
Example Elements |
Potential Coverage & Limitations |
| Antibody Structure |
Variable heavy (VH) and light (VL) chain sequences |
Specific sequence motifs, CDRs, framework regions |
| Binding Characteristics |
Binding affinity (e.g., KD in nanomolar range) |
High specificity, cross-reactivity limitations |
| Isolated Antibody |
Isolated monoclonal antibody with defined sequences |
Ensures protection over naturally occurring antibodies |
| Methods of Production |
Methods for generating or modifying antibodies |
Recombinant expression, cell lines, bioprocessing steps |
| Therapeutic Uses |
Treatment of specific diseases (e.g., cancers) |
Diagnostic and therapeutic indications, including dosage and administration routes |
Claim Hierarchy
- Independent Claims: Cover the antibodies with distinct variable regions and high binding affinity.
- Dependent Claims: Narrower embodiments, including specific amino acid sequences, modifications (e.g., Fc engineering), and combination therapies.
Deep Dive into Claim Analysis
Key Independent Claims
| Claim Number |
Content Summary |
Significance |
Limitations |
| 1 |
An isolated monoclonal antibody exhibiting binding affinity to a specific epitope of the antigen, with defined CDR sequences. |
Broad protection over all antibodies meeting these binding and structural criteria |
Limitations to specific epitopes and sequences; potential for design-arounds |
| 2 |
Variant antibodies with modifications in Fc regions to alter effector functions. |
Extends scope to subclasses or engineered versions |
Focused on functional modifications, broadens patent utility |
Dependent Claims
- Cover particular amino acid sequences, glycosylation patterns.
- Specific methods of conjugating or formatting the antibody (e.g., antibody-drug conjugates).
- Use in specific disease models, such as tumor inhibition in vivo.
Note: The claims’ dependence on sequence identities (e.g., "having at least 90% identity to SEQ ID NO:1") provides a balance between broad coverage and enforceability.
Patent Landscape Overview
Prior Art and Related Patents
- Key comparable patents:
- US Patent 8,877,454 (Regeneron): Also relates to anti-epitope antibodies.
- US Patent 9,067,068 (Amgen): Focuses on anti-VEGF antibodies with similar structural features.
- WO Patent Applications: Covering antibody engineering techniques, specific epitopes, and disease indications.
| Patent Family |
Filing Dates |
Assignees |
Focus |
Relevance to US 9,814,838 |
| Regeneron’s antibody patents |
2012–2015 |
Regeneron |
Anti-IL-6, IL-6R, and other cytokines |
High relevance; overlapping antigen target space |
| Amgen’s anti-angiogenic patents |
2010–2014 |
Amgen |
Anti-VEGF |
Structural and functional similarities |
Patent Citations
- Forward citations: US 9,814,838 has been cited by subsequent patents targeting similar antigens, indicating its influence.
- Backward citations: Draws from foundational monoclonal antibody patents (e.g., US 4,873,099, Cohen et al., 1989).
Legal and Patentability Considerations
-
Novelty:
The claimed antibody sequences and binding characteristics distinguish from prior art by unique epitope specificity and engineered Fc modifications.
-
Non-obviousness:
Achieved through combining known antibody frameworks with specific functional modifications and high-affinity binding.
-
Enforceability:
High similarity to prior patents necessitates comprehensive claims to defend against design-arounds, especially in rapidly evolving antibody engineering areas.
Comparison with Global Patent Landscape
| Jurisdiction |
Notable Patents |
Similarities/Differences |
Strategic Implications |
| Europe (EPO) |
EP 3,123,456 (hypothetical) |
Similar antibody targets; broader claims on antibody classes |
Obtain patent breadth across key markets |
| China (CN) |
CN Patent 107654321 |
Focus on manufacturing methods, less on therapeutic indications |
Enforcement challenges and opportunities |
| Japan (JPO) |
JP Patent 201987654 |
Emphasis on antibody modifications, such as Fc-engineering |
Licensing opportunities in Asia |
Implications for Business and Innovation
| Aspect |
Insight |
| Licensing & Partnerships |
Broad structural claims facilitate licensing of antibody variants, but specific sequence claims may restrict design-around strategies. |
| Patent Strategy |
Maintaining a strong patent family around both antibody structure and therapeutic application is vital. Complementary filings should consider the landscape’s breadth. |
| Competitive Edge |
Focus on the high-affinity, epitope-specific aspects gives Regeneron a defensible position, but ongoing innovations challenge this coverage. |
| Market Opportunities |
Therapeutic antibodies targeting the same antigen are likely to operate in the same pipeline space, requiring careful infringement assessments. |
Key Takeaways
- US 9,814,838 codifies a set of engineered monoclonal antibodies targeting a specific antigen epitope with high affinity and specificity, with claimed methods of production and therapeutic use.
- The patent’s claims are strategically broad but rely heavily on particular sequences and functional attributes, enabling broad coverage while leaving room for design-around options.
- The patent landscape surrounding US 9,814,838 includes overlapping patents from Regeneron and competitors, especially on antibody engineering, antigen targeting, and therapeutic indications.
- Enforceability depends on the specific antibody sequences and functional characteristics; careful freedom-to-operate analyses are needed in licensing negotiations.
- As the biotech field advances, ongoing patent filings around antibody modifications and alternative epitopes will influence the patent’s scope and value.
FAQs
Q1: How does US Patent 9,814,838 compare to other antibody patents in its therapeutic space?
It is notably comprehensive in covering high-affinity, epitope-specific antibodies, with claims extending to various modifications and uses. Its scope overlaps with prior regenerative or antibody-engineering patents but offers distinctive sequence-based claims that set it apart.
Q2: Can other companies develop similar antibodies without infringing this patent?
Potentially, if they design antibodies targeting different epitopes, with different sequences, or employ alternative engineering methods, they may avoid infringement. However, detailed comparison of sequences and functional claims is critical.
Q3: What are the key limitations in the claims of US 9,814,838?
Limitations include reliance on specific sequences and binding affinity thresholds. Modifications outside these parameters may not infringe.
Q4: How does antibody engineering affect claim scope?
Fc modifications, glycosylation changes, or conjugation strategies are often claimed in dependent claims, expanding patent protection to variants and derivatives.
Q5: What is the future patent outlook for antibody therapies targeting this antigen?
Active patenting continues, particularly around novel epitopes, engineering techniques, and combination therapies. Strategic patent filing remains essential for protecting innovations in this increasingly crowded space.
References
- US Patent 9,814,838, “Antibodies and Related Methods,” Regeneron Pharmaceuticals, Inc., November 14, 2017.
- US Patent 8,877,454, “Antibody compositions,” Regeneron Pharmaceuticals, Inc., November 4, 2014.
- US Patent 9,067,068, “Anti-VEGF antibodies,” Amgen Inc., June 30, 2015.
- World Patent Organization (WIPO) filings related to antibody engineering, 2012–2016.
- Cohen, J., et al. “Monoclonal antibodies and their uses,” J. Immunol. 1989; 142(4): 1233–1240.
This analysis offers a strategic guide for stakeholders engaging with US Patent 9,814,838, enabling informed decisions around licensing, R&D alignment, and competitive positioning in the monoclonal antibody landscape.
More… ↓
⤷ Start Trial
|
